“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

(2022) Poornima Sharma et al.   CLINICAL CANCER RESEARCH

Bispecific Antibodies for the Treatment of Multiple Myeloma

(2022) Scott R. Goldsmith et al.   Current Hematologic Malignancy Reports

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

(2022) Endeshaw Chekol Abebe et al.   Frontiers in Immunology

Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy

(2022) Samer Al Hadidi et al.   BONE MARROW TRANSPLANTATION

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

(2021) Mounzer E. Agha et al.   JOURNAL OF CLINICAL ONCOLOGY

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

(2021) Saad Z Usmani et al.   LANCET

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

(2021) Yael C. Cohen et al.   BLOOD

Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma

(2021) Dexiu Bu et al.   BLOOD

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

(2021) Amrita Y. Krishnan et al.   BLOOD

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

(2021) Luciano J. Costa et al.   Clinical Lymphoma Myeloma & Leukemia

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

(2020) Zachary Jackson et al.   Frontiers in Immunology

Automated generation of gene-edited CAR T cells at clinical scale

(2020) Jamal Alzubi et al.   Molecular Therapy-Methods & Clinical Development

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

(2019) Cesar Sommer et al.   MOLECULAR THERAPY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD